Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Apr:172:103639.
doi: 10.1016/j.critrevonc.2022.103639. Epub 2022 Feb 19.

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Marco Tagliamento  1 , Paolo Bironzo  2 , Hubert Curcio  3 , Emmanuele De Luca  4 , Daniele Pignataro  5 , Simonetta G Rapetti  6 , Marco Audisio  6 , Valentina Bertaglia  6 , Chiara Paratore  6 , Maristella Bungaro  6 , Emanuela Olmetto  6 , Elisa Artusio  6 , Maria Lucia Reale  6 , Clizia Zichi  4 , Enrica Capelletto  6 , Simona Carnio  6 , Lucio Buffoni  7 , Francesco Passiglia  6 , Silvia Novello  6 , Giorgio Vittorio Scagliotti  6 , Massimo Di Maio  4
Affiliations
Free article
Meta-Analysis

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Marco Tagliamento et al. Crit Rev Oncol Hematol. 2022 Apr.
Free article

Abstract

Introduction: Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM.

Methods: A systematic review of the literature of clinical trials testing single-agent anti PD-1/PD-L1 ICIs in pre-treated asMM was performed. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) data were extracted. The predictive role of PD-L1 was assessed.

Results: We selected 13 studies including 888 patients. ORR and DCR were 18.1% (95% confidence interval [CI] 13.9-22.8%) and 55.4% (95% CI: 48.1-62.5%), respectively. Median PFS and OS ranged from 2.1 to 5.9 and from 6.7 to 20.9 months, respectively. ORR according to PD-L1 was 27.0% (95% CI: 18.7-36.2%).

Conclusions: Anti-PD-(L)1 ICIs might be considered a treatment option for chemotherapy-resistant asMM, even if reliable predictive factors are still lacking.

Keywords: Avelumab; Immune checkpoint inhibitors; Mesothelioma; Nivolumab; Pembrolizumab.

PubMed Disclaimer

MeSH terms

Substances